chlorthalidone has been researched along with probenecid in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Baer, JE; Beyer, KH | 1 |
| Freis, ED; Sappington, RF | 1 |
| Campíns-Falcó, P; Herráez-Hernández, R; Sevillano-Cabeza, A | 1 |
| BEISEL, WR; FORSHAM, PH; SMILO, RP | 1 |
| DENKO, CW | 1 |
1 review(s) available for chlorthalidone and probenecid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for chlorthalidone and probenecid
| Article | Year |
|---|---|
Long-term effect of probenecid on diuretic-induced hyperuricemia.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Pressure Determination; Body Weight; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Kidney Tubules; Male; Middle Aged; Potassium; Probenecid; Uric Acid | 1966 |
11 other study(ies) available for chlorthalidone and probenecid
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
The site and mode of action of some sulfonamide-derived diuretics.
Topics: Acetazolamide; Aminohippuric Acids; Animals; Carbonic Anhydrase Inhibitors; Chemical Phenomena; Chemistry; Chlorides; Chlorothiazide; Chlorthalidone; Cyclopenthiazide; Depression, Chemical; Dichlorphenamide; Diffusion; Diuretics; Hydrochlorothiazide; Kidney Cortex; Kidney Medulla; Natriuresis; Probenecid; Rabbits; Sodium; Trichlormethiazide | 1975 |
Improved detection limits for screening of diuretics by coupled liquid chromatography and ultraviolet-visible spectrophotometry.
Topics: Chlorthalidone; Chromatography, High Pressure Liquid; Diuretics; Humans; Indicators and Reagents; Probenecid; Reference Standards; Spectrophotometry, Ultraviolet | 1993 |
Reversal of thiazide-induced transient hyperuricemia by uricosuric agents.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hyperuricemia; Probenecid; Pyrazoles; Thiazides; Uric Acid; Uricosuric Agents | 1962 |
TREATMENT OF THE PATIENT WITH GOUT.
Topics: Chlorthalidone; Colchicine; Diagnosis; Gout; Humans; Oxyphenbutazone; Phenylbutazone; Probenecid; Pyrazoles; Salicylates; Sulfinpyrazone; Uricosuric Agents | 1963 |